Nektar Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nektar Therapeutics generated cash of -$192,606,000, which is more than the previous year. Cash used in financing activities reached the amount of $30,000 last year. Net change in cash is therefore -$52,950,000.
Cash Flow
| 2014 | -142.00M | -37.57M | 152.98M |
|---|---|---|---|
| 2015 | -73.08M | -14.33M | 130.78M |
| 2016 | -117.02M | -82.4M | 203.61M |
| 2017 | -80.41M | -28.80M | 54.39M |
| 2018 | 718.21M | -1.37B | 851.96M |
| 2019 | -328.68M | 206.88M | 23.35M |
| 2020 | -313.28M | 496.21M | -80.35M |
| 2021 | -412.66M | 202.77M | 36.23M |
| 2022 | -304.00M | 365.83M | 1.50M |
| 2023 | -192.60M | 139.56M | 30K |
NKTR Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 88.22M | 25.21M | 198.95M | 96.36M | 194.90M | 4.76M | 59.64M | 55.57M | 12.36M | 39.06M |
Operating activities | ||||||||||
Net income | -276.05M | -368.19M | -523.83M | -444.44M | -440.66M | 681.31M | -96.69M | -153.52M | -81.17M | -53.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 7.81M | 13.03M | 14.14M | 14.18M | 13.15M | 10.87M | 14.74M | 15.35M | 12.85M | 12.92M |
Stock-based compensation expense | 33.38M | 57.32M | 94.67M | 94.26M | 99.79M | 0 | 36.61M | 25.85M | 19.66M | 17.01M |
| Deferred income tax benefit | 33.38M | 57.32M | 94.67M | 94.26M | 99.79M | 0 | 36.61M | 25.85M | 19.66M | 17.01M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 4.77M | 16.51M | 12.39M | 1.91M | 6.41M | -25.50M | 10.66M | 4.26M | -16.34M | -1.37M |
Inventories | 699K | -3.40M | -509K | -2.62M | -1.28M | -655K | 383K | 237K | 1.60M | 500K |
Accounts payable | -2.88M | 3.10M | -11.69M | 2.38M | 12.96M | 971K | 2.07M | 518K | -412K | -6.35M |
Cash generated by operating activities | -192.60M | -304.00M | -412.66M | -313.28M | -328.68M | 718.21M | -80.41M | -117.02M | -73.08M | -142.00M |
Investing activities | ||||||||||
Purchases Of Investments | -511.69M | -467.91M | -960.68M | -987.53M | -1.38B | -2.27B | -404.42M | -334.65M | -297.60M | -297.25M |
Investments In Property Plant And Equipment | -865K | -5.67M | -14.98M | -7.25M | -26.28M | -14.23M | -9.67M | -6.39M | -11.19M | -9.97M |
Acquisitions Net | 0 | 13.19M | -217.76M | -503.47M | -233.17M | 2.63M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 139.56M | 365.83M | 202.77M | 496.21M | 206.88M | -1.37B | -28.80M | -82.4M | -14.33M | -37.57M |
Financing activities | ||||||||||
Common Stock Issued | 30K | 758K | 33.23M | 23.39M | 23.35M | 0 | 59.52M | 189.27M | 32.20M | 116.53M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -250M | 0 | 0 | -5.13M | -5.94M | 98.57M | -3.53M |
Cash used in financing activities | 30K | 1.50M | 36.23M | -80.35M | 23.35M | 851.96M | 54.39M | 203.61M | 130.78M | 152.98M |
Net Change In Cash | -52.95M | 63.00M | -173.73M | 102.59M | -98.54M | 190.14M | -54.87M | 4.07M | 43.20M | -26.70M |
Cash at end of period | 35.27M | 88.22M | 25.21M | 198.95M | 96.36M | 194.90M | 4.76M | 59.64M | 55.57M | 12.36M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |